文献速递前列腺癌

Decipher基因组分类器在前列腺癌中证据的系统综述

A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.
PubMed 文献 · Eur Urol · 2020-12-05

该研究系统检索2010年1月至2020年6月PubMed及会议摘要,纳入42项研究共30407例前列腺癌患者,按Simon等及AUA标准评估Decipher基因组分类器(GC)的临床效用。GC在32项研究中经多变量分析为所有研究终点独立预后因素,并在24项研究中改善对标准治疗的判别;GC使用改变了主动监测(NNT=9)及前列腺切除术后(NNT=1.5-4)的管理决策。结论认为GC在前列腺癌中具有临床效用,尤以中危前列腺癌及前列腺切除术后决策最强。

要点

  • GC在32项研究(n=12600)中为所有终点独立预后因素。
  • GC在24项研究(n=8543)中改善对标准治疗的判别。
  • GC改变主动监测管理NNT=9,改变术后管理NNT=1.5-4。

核心结论

  • 来自不同证据水平的一致数据表明Decipher基因组分类器在前列腺癌中具有临床效用。
  • GC的效用在中危前列腺癌和前列腺切除术后决策中最为突出。

研究设计与样本

  • 按PRISMA指南系统检索PubMed和会议摘要,时间范围为2010年1月至2020年6月。
  • 共纳入42项研究、30407例患者,证据按Simon等和AUA标准分级。
  • GC性能数据来自回顾性研究(n=12141)、前瞻性登记(n=17053)及前瞻性和事后随机试验分析(n=1213)。

主要发现

  • 在32项研究(n=12600)中,GC经多变量分析为所有研究终点(不良病理、生化失败、转移、癌症特异性和总生存)的独立预后因素。
  • 在24项研究(n=8543)中,GC改善了相对于标准治疗的判别能力。
  • 在5项研究(n=4331)中,GC使用改变了主动监测(NNT=9)和前列腺切除术后(NNT=1.5-4)的管理。

关键数值与推荐

  • 除高危前列腺癌外,所有疾病状态的证据强度按Simon标准为1级和2级。
  • 按AUA标准,证据等级为A级和B级,取决于疾病状态。

临床怎么用

  • GC可用于中危前列腺癌的风险分层,辅助个体化治疗决策。
  • GC可用于前列腺切除术后决策,帮助识别需要更积极治疗的患者。
  • GC可辅助主动监测的入选决策,NNT=9提示每9例检测可改变1例管理。

局限性

  • 证据主要来自回顾性研究、前瞻性登记及事后分析,随机试验数据有限(n=1213)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use. OBJECTIVE: To perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier (GC). EVIDENCE ACQUISITION: The review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by searching PubMed and conference abstracts from January 2010 to June 2020. Evidence was then graded using the criteria of Simon et al (Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52) and American Urology Association (AUA) criteria. EVIDENCE SYNTHESIS: In total, 42 studies and 30407 patients were included. GC performance data were available for localized, postprostatectomy, nonmetastatic castration-resistant, and metastatic hormone-sensitive PCa as part of retrospective studies (n=12141), prospective registries (n=17053), and prospective and post hoc randomized trial analyses (n=1213). In 32 studies (n=12600), the GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) on multivariable analysis and improved the discrimination over standard of care in 24 studies (n=8543). GC use changed the management in active surveillance (number needed to test [NNT]=9) and postprostatectomy (NNT=1.5-4) settings in five studies (n=4331). Evidence strength was levels 1 and 2 by the Simon criteria for all disease states other than high-risk PCa, and grades A and B by AUA criteria depending on disease state. CONCLUSIONS: Consistent data are now present from diverse levels of evidence, which when viewed together, have demonstrated clinical utility of the GC in PCa. The utility of the GC is strongest for intermediate-risk PCa and postprostatectomy decision-making. PATIENT SUMMARY: In this paper, we review the evidence of the Decipher genomic classification tool for men with prostate cancer. We found consistent evidence that the test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision-making.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Jairath NK, Dal Pra A, Vince R, et al. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2020. PMID: 33293078. doi:10.1016/j.eururo.2020.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。